During the ASH meeting in San Diego 2024, I have the opportunity to present the results regarding the use of MaaT013 that is a pooled micro biotherapeutic product that has a high diversity that we can use to treat acute graft-versus-host disease, and in fact we are able to use this drug in 140 patients, more than that now but we have the data for the first 140 patients that received this treatment to treat GI acute graft-versus-host disease that are resistant to steroids...
During the ASH meeting in San Diego 2024, I have the opportunity to present the results regarding the use of MaaT013 that is a pooled micro biotherapeutic product that has a high diversity that we can use to treat acute graft-versus-host disease, and in fact we are able to use this drug in 140 patients, more than that now but we have the data for the first 140 patients that received this treatment to treat GI acute graft-versus-host disease that are resistant to steroids. In fact, patients are not only resistant to steroids because they receive a median of two lines of treatment up to six lines of treatment. So in these very severe patients with GI acute graft-versus-host disease, they receive three treatments with MaaT013, so this is some FMT product that is off the shelf that is readily available with high diversity, as I just told you on. In particular a high number of butyrate-producing bacteria.
And in fact when we look at the result it was really amazing because we had an overall response rate of 51% for GI responses. But we also have some patients that have also some skin and liver involvement and in fact in those patients we also achieved some response on the skin and the liver with no additional immunosuppressive treatments.
We also look more closely in patients that received steroids first line, ruxolitinib second line and that received MaaT013 at the third line of treatment because this is truly where we have the unmet medical need for patients who received steroids and ruxolitinib. In fact in those patients the response rate was even higher, 55% overall response rate, and the response was sustained because at day 56, one month later we still have a very high response rate and it translates to a very good overall survival at one year. So we really believe that this treatment will be the next generation treatment that we will use in this setting of patients that are resistant to steroids and ruxolitinib. In fact we ran Phase III clinical trial in this setting. All patients have been included and I really hope that they will be able to present as ASH next week the result of this Phase III clinical trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
